Actinium Pharmaceuticals, Inc. Cash Flow Statement
ATNM|6 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$25M
FY2025
Free Cash Flow
-$25M
FY2025
Capital Expenditures
$104,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Actinium Pharmaceuticals, Inc. used $25M in operating cash flow and negative free cash flow of $25M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2011 |
|---|---|---|---|---|---|---|
| Net Income | -$33.9M | -$48.8M | -$33.0M | -$24.8M | -$22.2M | -$3.4M |
| Depreciation & Amortization | $173.0K | $207.0K | $699.0K | $524.0K | $447.0K | $633 |
| Operating Cash Flow | -$24.6M | -$47.3M | $8.6M | -$20.9M | -$21.6M | -$517.6K |
| Capital Expenditures | $104.0K | $153.0K | $366.0K | $133.0K | $253.0K | - |
| Free Cash Flow | -$24.7M | -$47.5M | $8.3M | -$21.0M | -$21.9M | - |
| FCF Margin | -27426.7% | -58627.2% | 803.7% | -1835.6% | -1911.7% | - |